Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
In all but one of the patient cases, calcium and vitamin D supplementation were either reduced or discontinued completely after a formal diagnosis and a lower serum calcium level (depending on patient tolerance and symptoms) was accepted as a physiological baseline.
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case series.
Case series
Describes a group of individual cases.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England
Source: Article title.
Patients were consented to a national rare disease registry (RaDaR) () ().
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England
Case series · Journal of the Endocrine Society · 2026
Original publication title
Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England
© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To describe a case series of adults with genetically confirmed AHD1.
Source: ObjectiveAbstract: What methods does the paper describe?
We reviewed 9 adults with genetically confirmed ADH1 in North East England (2005-2024). Clinical, biochemical, and imaging data were retrospectively analyzed from electronic records. Pathogenic CASR variants were identified via accredited genomic panels.
Source: MethodsAbstract: Context
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder caused by activating CASR variants, characterized by hypocalcemia, low/normal parathyroid hormone, and hypercalciuria. While managed with conservative calcium targets to prevent renal damage, the long-term systemic burden remains poorly defined.
Source: ContextAbstract: Results
The cohort (n = 9; 5 female; age 24-57) was 89% familial, with all exhibiting persistent hypocalcemia and 66% presenting with hypomagnesemia. Renal involvement affected 78%, including nephrocalcinosis (56%), nephrolithiasis (67%), and chronic kidney disease (CKD), with 2 patients from 1 kindred progressing to kidney failure (KF) and death. Extrarenal features included seizures, intracranial calcifications, dental abnormalities, and neuropsychiatric symptoms, often persisting despite conservative strategies to limit calcium supplementation post diagnosis. No clear correlation was found between mean serum calcium levels and disease severity, highlighting substantial phenotypic variability.
Source: ResultsAbstract: Conclusion
ADH1 is a multisystem disorder with substantial morbidity, including nephrocalcinosis, CKD, and a risk of KF despite cautious management. Other significant features include hypocalcemic seizures and intracranial calcification. These findings emphasize the necessity of early genetic diagnosis, family screening, and longitudinal renal surveillance. The high complication burden under conventional therapy underscores the need for targeted treatments, such as CaSR antagonists (calcilytics), to improve long-term outcomes.
Source: ConclusionAuthors’ abstract
Abstract
Context
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder caused by activating CASR variants, characterized by hypocalcemia, low/normal parathyroid hormone, and hypercalciuria. While managed with conservative calcium targets to prevent renal damage, the long-term systemic burden remains poorly defined.
Objective
To describe a case series of adults with genetically confirmed AHD1.
Methods
We reviewed 9 adults with genetically confirmed ADH1 in North East England (2005-2024). Clinical, biochemical, and imaging data were retrospectively analyzed from electronic records. Pathogenic CASR variants were identified via accredited genomic panels.
Results
The cohort (n = 9; 5 female; age 24-57) was 89% familial, with all exhibiting persistent hypocalcemia and 66% presenting with hypomagnesemia. Renal involvement affected 78%, including nephrocalcinosis (56%), nephrolithiasis (67%), and chronic kidney disease (CKD), with 2 patients from 1 kindred progressing to kidney failure (KF) and death. Extrarenal features included seizures, intracranial calcifications, dental abnormalities, and neuropsychiatric symptoms, often persisting despite conservative strategies to limit calcium supplementation post diagnosis. No clear correlation was found between mean serum calcium levels and disease severity, highlighting substantial phenotypic variability.
Conclusion
ADH1 is a multisystem disorder with substantial morbidity, including nephrocalcinosis, CKD, and a risk of KF despite cautious management. Other significant features include hypocalcemic seizures and intracranial calcification. These findings emphasize the necessity of early genetic diagnosis, family screening, and longitudinal renal surveillance. The high complication burden under conventional therapy underscores the need for targeted treatments, such as CaSR antagonists (calcilytics), to improve long-term outcomes.
Publication and source details
Original title: Renal and systemic complications in autosomal dominant hypocalcemia type 1: a case series from North East England
Deepika Manoharan; Edwin K S Wong; Holly Mabillard; Shalabh Srivastava; Simon H S Pearce; John A Sayer
Journal of the Endocrine Society · 2026
Correspondence: John A. Sayer, MB ChB, PhD, Faculty of Medical Sciences, Biosciences Institute, Newcastle University, Central Parkway, Newcastle Upon Tyne, Tyne and Wear, NE1 3BZ, UK. Email: John.sayer@newcastle.ac.uk.© The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. MRC10.13039/501100020643 MR/V028723/1MR/Y007808/1MR/V005898/1 LifeArc10.13039/100012357 Kidney Research UK10.13039/501100000291 RP_007_20210729 Northern Counties Kidney Research Fund10.13039/501100004185 20/01Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:45:34.070962+00:00
DOI: 10.1210/jendso/bvag205 · PMC13595229